Fasenra Dosage/Direction for Use

Fasenra treatment should be initiated by a physician experienced in the diagnosis and treatment of conditions for which benralizumab is indicated (see Indications/Uses).
After proper training in the subcutaneous injection technique and education about signs and symptoms of hypersensitivity reactions (see Precautions), patients with no known history of anaphylaxis or their caregivers may administer FASENRA if their physician determines that it is appropriate, with medical follow-up as necessary. Self-administration should only be considered in patients already experienced with FASENRA treatment.
Posology: FASENRA is intended for long-term treatment. A decision to continue the therapy should be made at least annually based on disease severity, level of disease control, and blood eosinophil counts.
Asthma: The recommended dose is 30 mg of FASENRA by subcutaneous injection every 4 weeks for the first 3 doses, and then every 8 weeks thereafter.
EGPA: The recommended dose of benralizumab is 30 mg by subcutaneous injection every 4 weeks.
Patients who develop life-threatening manifestations of EGPA should be evaluated for the need for continued therapy, as FASENRA has not been studied in this population.
Missed Dose: If an injection is missed on the planned date, dosing should resume as soon as possible on the indicated regimen; a double dose must not be administered.
Paediatric population: The safety and efficacy of FASENRA in children and adolescents less than 18 years with asthma have not been established. No data are available for children aged less than 12 years old. Currently available data in children 12 to less than 18 years old are described in Adverse Reactions, Pharmacology: Pharmacodynamics and Pharmacokinetics under Actions, but no recommendation on a posology can be made.
The safety and efficacy of FASENRA in children and adolescents less than 18 years with EGPA have not been established.
Elderly patients: No dose adjustment is required for elderly patients (see Pharmacology: Pharmacokinetics under Actions).
Renal and hepatic impairment: No dose adjustment is required for patients with renal or hepatic impairment (see Pharmacology: Pharmacokinetics under Actions).
Method of administration: FASENRA is administered as a subcutaneous injection.
Pre-filled syringe: In line with clinical practice, monitoring of patients after administration of biologic agents is recommended (see Hypersensitivity reactions under Precautions).
Administer FASENRA into the upper arm, thigh, or abdomen.
Pre-filled pen: It should be injected into the thigh or abdomen. If the healthcare professional or caregiver administers the injection, the upper arm can also be used. It should not be injected into areas where the skin is tender, bruised, erythematous, or hardened.
Comprehensive instructions for administration using the pre-filled pen are provided in the 'Instructions for Use' under Patient Counselling Information.